Induction

The first phase of treatment, aimed at bringing a flare under control. Often uses higher or more frequent doses.

Also called: induction therapy, loading dose, induction phase

Related words maintenance induction of remission

Topics Research Medicines

Where to read more

British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025

British Society of Gastroenterology Guideline Jun 2025 For professionals

The current UK specialist guideline for managing IBD in adults, replacing the 2019 version. It is designed to sit alongside the IBD Standards and encourage use of the national primary care pathway for lower gut symptoms so diagnosis is quicker and more accurate. Among its general principles, it recommends classifying Crohn's using the Montreal system.

Topics About Crohn's disease Diagnosis and tests Medicines Monitoring Complications Surgery

Jargon explained Montreal classification remission endoscopic remission inflammatory bowel disease advanced therapy GRADE induction maintenance

ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment

European Crohn's and Colitis Organisation (J Crohns Colitis) Guideline Oct 2024 For professionals

Europe's main expert guideline on which medicines to use for Crohn's disease, published as the first of a two-part set (the second covers surgery). It weighs up the trial evidence for steroids, immunosuppressants, biologics and newer tablets, including treatment of disease around the back passage. UK specialists use it alongside the BSG guideline.

Topics Medicines Biologics and newer medicines Immunosuppressants Around the bottom (perianal)

Jargon explained biologic immunomodulator induction maintenance de-escalation perianal fistula GRADE

Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children (REACH)

Gastroenterology Study Mar 2007 Patients and professionals

The key trial of infliximab in 112 children with moderate to severe Crohn's. After the first three doses, 88% had improved and 59% were in remission. Children given the drug every 8 weeks afterwards did better at one year than those given it every 12 weeks. It led to infliximab being used for children.

Topics Children and young people Biologics and newer medicines

Jargon explained induction maintenance clinical response PCDAI

Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease (UNITI)

New England Journal of Medicine Study Nov 2016 Patients and professionals

The trials that led to ustekinumab (Stelara) being used for Crohn's. A first drip of ustekinumab helped more people improve than a dummy drip, and injections every 8 or 12 weeks afterwards kept about half of responders in remission at week 44, against about 36% on placebo. Side effects were similar between groups.

Topics Biologics and newer medicines

Jargon explained induction maintenance IL-12/23 placebo

Vedolizumab as induction and maintenance therapy for Crohn's disease (GEMINI 2)

New England Journal of Medicine Study Aug 2013 Patients and professionals

The main trial of vedolizumab (Entyvio) in Crohn's. It helped more people reach remission than placebo by week 6, and people who responded and stayed on it were more likely to be in remission at one year. Side effects, including infections, were somewhat more common than on placebo in this trial.

Topics Biologics and newer medicines

Jargon explained integrin induction maintenance serious adverse event

Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials

The Lancet Study May 2022 Patients and professionals

Two trials testing risankizumab (Skyrizi) drips to bring active Crohn's under control, including in people for whom other biologics had failed. Risankizumab led to more remissions, and more improvement seen on camera tests of the bowel, at 12 weeks than placebo, and was generally well tolerated.

Topics Biologics and newer medicines

Jargon explained induction phase 3 trial endoscopic response

Upadacitinib Induction and Maintenance Therapy for Crohn's Disease (U-EXCEL, U-EXCEED, U-ENDURE)

New England Journal of Medicine Study May 2023 Patients and professionals

Three trials of upadacitinib (Rinvoq), a daily tablet rather than an injection or drip. It worked better than placebo both for settling active Crohn's over 12 weeks and for keeping it settled over a year. Some side effects, such as liver changes, low white cells and a few cases of bowel perforation, were seen more on the drug, so it needs monitoring.

Topics Medicines Immunosuppressants Research

Jargon explained JAK inhibitor small molecule induction maintenance herpes zoster endoscopic response

Antibiotics for induction and maintenance of remission in Crohn's disease

Cochrane Systematic review Feb 2019 Patients and professionals

Antibiotics may give a small benefit for active Crohn's, but probably not enough to make a real difference for most people. They did not cause more side effects than placebo. Whether they help keep Crohn's in remission is unclear. Note this is about treating the Crohn's itself, not infections or abscesses.

Topics Medicines Research

Jargon explained antibiotic clinically meaningful antibiotics induction maintenance

Vedolizumab for induction and maintenance of remission in Crohn's disease

Cochrane Systematic review Jul 2023 Patients and professionals

Pooling several trials, Cochrane found high-certainty evidence that vedolizumab (Entyvio) works better than placebo both for bringing on remission and keeping it. Overall side effects were probably similar to placebo. Head-to-head comparisons with other biologics are still needed.

Topics Biologics and newer medicines Research

Jargon explained high-certainty evidence induction maintenance integrin

Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease

Cochrane Systematic review May 2025 Patients and professionals

Updated Cochrane review of ustekinumab (Stelara) and related drugs for active Crohn's. It found ustekinumab helps bring on remission by eight weeks and probably does not cause more serious side effects than placebo. There was not enough data to choose the best dose for children, and comparisons with other biologics are very uncertain.

Topics Biologics and newer medicines

Jargon explained IL-12/23 induction certainty of evidence

Search everything for "induction"